PULSAR radiation with immunotherapy and chemo for liver metastases
Treatments studied
Part of Cancer clinical trials.
This trial tests a new approach combining a special type of radiation (PULSAR) with immunotherapy and chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to the liver (stage M1).
- You can still perform daily activities without much help (Karnofsky score 70 or higher).
- You have not received any chemotherapy or other cancer treatment before joining this trial.
- Your tumor type is MSS or pMMR (two common types that don't respond to immunotherapy alone).
- You do not have other serious health conditions like heart disease or autoimmune disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
This trial tests a special type of radiation called PULSAR combined with an immunotherapy drug (anti-PD-1) in people whose cancer has spread within the abdomen or pelvis. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of precise radiation to liver or lung tumors plus immunotherapy for people with advanced colorectal cancer that cannot be surgically removed. It aims to see if this approach can help control the cancer.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted therapy (bevacizumab) to shrink liver metastases from colorectal cancer that cannot be surgically removed right now. The goal is to make the tumors small enough for surgery.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
Hear when a new Colorectal Cancer Liver Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.